Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as first-line treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database.
Akihiko UedaHidemichi WatariMasaki MandaiShunichi FukuharaYasuo SugitaniKiyoko OginoShuichi KamijimaTakayuki EnomotoPublished in: Journal of gynecologic oncology (2022)
No notable increase was observed in GI perforation associated with NAC containing bevacizumab. We conclude that bevacizumab is prescribed with sufficient care in Japan to avoid GI perforation.
Keyphrases
- neoadjuvant chemotherapy
- healthcare
- metastatic colorectal cancer
- locally advanced
- lymph node
- sentinel lymph node
- papillary thyroid
- transcription factor
- palliative care
- risk factors
- health insurance
- squamous cell
- quality improvement
- squamous cell carcinoma
- radiation therapy
- early stage
- lymph node metastasis
- young adults
- health information
- adverse drug
- chronic pain